Abstract

Human lung cancer is a disease with high incidence and accounts for most cancer-related deaths in both men and women. Metastasis is a common event in non-small cell lung carcinoma (NSCLC), diminishing the survival chance of the patients with this type of tumor. It has been shown that MYC is involved in the development of metastasis from NSCLC, but the mechanism underlying this switch remained to be identified. Here, we focus on GATA4 as a MYC target in the development of metastasis with origin in lung adenocarcinoma, the most common type of NSCLC. Epigenetic alterations at the GATA4 promoter level were observed after MYC expression in lung adenocarcinoma in vivo and in vitro. Such alterations include site-specific demethylation that accompanies the displacement of the MYC-associated zinc finger protein (MAZ) from the GATA4 promoter, which leads to GATA4 expression. Histone modification analysis of the GATA4 promoter revealed a switch from repressive histone marks to active histone marks after MYC binding, which corresponds to active GATA4 expression. Our results thus identify a novel epigenetic mechanism by which MYC activates GATA4 leading to metastasis in lung adenocarcinoma, suggesting novel potential targets for the development of antimetastatic therapy.

Highlights

  • Non–small cell lung carcinoma (NSCLC) is the most frequent type of lung cancer with high metastatic potential and a low cure rate

  • The MYC-ER virus encoding a fusion of the murine estrogen receptor (ER) and human c-MYC, GATA4 short hairpin RNA, and MYC-associated zinc finger protein (MAZ) shRNAproducing virus were independently produced in the Phoenix amphotrophic packaging cell line

  • As we found MAZ to be displaced from the GATA4 promoter after MYC expression in A549 cells, we predicted that the knockdown of MAZ in A549 cells could lead to GATA4 upregulation

Read more

Summary

Introduction

Non–small cell lung carcinoma (NSCLC) is the most frequent type of lung cancer with high metastatic potential and a low cure rate. Cancer has been classified as a genetic disease ever since the discovery of retroviral oncogenes and the finding of frequent mutations in their cellular counterparts in human tumors. Epigenetic silencing is known to be a frequent event in NSCLC, that is, of p16, H-cadherin, death-associated protein (DAP) kinase 1 (DAPK1), 14-3-3 sigma, and the Authors' Affiliations: 1Biocenter, Department of Microbiology, University of Wu€rzburg, Wu€rzburg; 2Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg; 3Department of General Surgery, University Hospital Rechts der Isar, Technical University of Munich, Munich; 4Division Molecular Mechanisms in Lung Cancer, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; and 5Beatson Institute for Cancer Research, Glasgow, United Kingdom.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call